Studies on the antimicrobial activity of cecropin A-melittin hybrid peptides in colistin-resistant clinical isolates of Acinetobacter baumannii

Journal of Antimicrobial Chemotherapy

Volumn 58, Issue 1, 2006, Pages 95-100

  Rodríguez Hernández, María Jesús ^a   Saugar, José ^b   Docobo Pérez, Fernando ^a   de la Torre, Beatriz G ^c   Pachón Ibáñez, María Eugenia ^a   García Curiel, Andrés ^a   Fernández Cuenca, Felipe ^d   Andreu, David ^c   Rivas, Luis ^b   Pachón, Jerónimo ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^c UNIVERSITAT POMPEU FABRA   (Spain)

^d UNIVERSITY OF SEVILLE   (Spain)

Author keywords

A. baumannii; Bactericidal activity; Capsule; Colistin resistance; Polymyxin

Indexed keywords

ANTIBIOTIC AGENT; CECROPIN A MELITTIN HYBRID PEPTIDE; COLISTIN; HYBRID PROTEIN; INDIAN INK; PEPTIDE DERIVATIVE; POLYMYXIN B; UNCLASSIFIED DRUG;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; COLISTIN; DRUG RESISTANCE, BACTERIAL; HUMANS; MELITTEN; POLYMYXINS; RECOMBINANT PROTEINS; TIME FACTORS;

EID: 33748038755     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl145     Document Type: Article

References (61)

1. Cisneros JM, Pachón J. Acinetobacter baumannii: A nosocomial pathogen difficult to control. Enferm Infect Microbiol Clin 2003; 21: 221
2. Cisneros JM, Reyes MJ, Pachón J et al. Bacteremia due to Acinetobacter baumannii: Epidemiology, clinical findings, and prognostic features. Clin Infect Dis 1996; 22: 1026-32.
3. Seifert H, Strate A, Pulverer G. Nosocomial bacteremia due to Acinetobacter baumannii. Clinical features, epidemiology, and predictors of mortality. Medicine (Baltimore) 1995; 74: 340-9.
4. Ribera A, Fernández-Cuenca F, Beceiro A et al. Antimicrobial susceptibility and mechanisms of resistance to quinolones and β-lactams in Acinetobacter genospecies 3. Antimicrob Agents Chemother 2004; 48: 1430-2.
5. 21 and cecropin P1. Antimicrob Agents Chemother 2001; 45: 994-5.
6. Van Looveren M, Goossens H. Antimicrobial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infect 2004; 10: 684-704.
7. Gallego L, Canduela MJ, Sevillano E et al. Carbapenemase detection in Acinetobacter baumannii clones resistant to imipenem. Enferm Infecc Microbiol Clin 2004; 22: 262-6.
8. Jain R, Danziger LH. Multidrug-resistant Acinetobacter infections: An emerging challenge to clinicians. Ann Pharmacother 2004; 38: 1449-59.
9. Jiménez-Mejías ME, Becerril B, Márquez-Rivas FJ et al. Successful treatment of multidrug-resistant Acinetobacter baumannii meningitis with intravenous colistin sulfomethate sodium. Eur J Clin Microbiol Infect Dis 2000; 19: 970-1.
10. Markou N, Apostolakos H, Kournoudiou C et al. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care 2003; 7: R78-83.
11. Sarria JC, Angulo-Pernett F, Kimbrough RC et al. Use of intravenous polymyxin B during continuous venovenous hemodialysis. Eur J Clin Microbiol Infect Dis 2004; 23: 340-1.
12. Fernández-Viladrich P, Corbella X, Corral L et al. Successful treatment of ventriculitis due to carbapenem-resistant Acinetobacter baumannii with intraventricular colistin sulfomethate sodium. Clin Infect Dis 1999; 28: 916-7.
13. Jimenez-Mejias ME, Pichardo-Guerrero C, Marquez-Rivas FJ et al. Cerebrospinal fluid penetration and pharmacokinetic/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis. Eur J Clin Microbiol Infect Dis 2002; 21: 212-4.
14. Siegman-Igra Y, Bar-Yosef S, Gorea A et al. Nosocomial Acinetobacter meningitis secondary to invasive procedures: Report of 25 cases and review. Clin Infect Dis 1993; 17: 843-9.
15. Vasen W, Desmery P, Ilutovich S et al. Intrathecal use of colistin. J Clin Microbiol 2000; 38: 3523.
16. Rodriguez-Hernandez MJ, Jimenez-Mejias ME, Pichardo C et al. Colistin efficacy in an experimental model of Acinetobacter baumannii endocarditis. Clin Microbiol Infect 2004; 10: 581-4.
17. Manikal VM, Landman D, Saurina G et al. Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: Citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin Infect Dis 2000; 31: 101-6.
18. Henwood CJ, Gatward T, Warner M et al. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). J Antimicrob Chemother 2002; 49: 479-87.
19. Alarcón T, López-Hernández S, Andreu D et al. In vitro activity of CA(1-8)M(1-18), a synthetic cecropin A-melittin hybrid peptide, against multiresistant Acinetobacter baumannii strains. Rev Esp Quimioter 2001; 14: 184-90.
20. 2 against multidrug-resistant nosocomial isolates of Acinetobacter baumannii. Peptides 2003; 24: 1315-8.
21. Rivas L, Andreu D. Eukaryotic antibiotic peptides: A new alternative in clinical practice? Enferm Infect Microbiol Clin 2003; 21: 358-65.
22. Saugar JM, Alarcón T, López-Hernández S et al. Activities of polymyxin B and cecropin A-melittin peptide CA(1-8)M(1-18) against a multiresistant strain of Acinetobacter baumannii. Antimicrob Agents Chemother 2002; 46: 875-8.
23. Bowdish DM, Davidson DJ, Hancock REW. A re-evaluation of the role of host defence peptides in mammalian immunity. Curr Protein Pept Sci 2005; 6: 35-51.
24. Jerala R, Porro M. Endotoxin neutralizing peptides. Curr Top Med Chem 2004; 4: 1173-84.
25. Yeaman MR, Yount NY. Mechanisms of antimicrobial peptide action and resistance. Pharmacol Rev 2003; 55: 27-55.
26. Reddy KV, Yedery RD, Aranha C. Antimicrobial peptides: Premises and promises. Int J Antimicrob Agents 2004; 24: 536-47.
27. Calandra T. Pathogenesis of septic shock: Implications for prevention and treatment. J Chemother 2001; 13: 173-80.
28. David SA, Awasthi SK, Balaram P. The role of polar and facial amphipathic character in determining lipopolysaccharide-binding properties in synthetic cationic peptides. J Endotoxin Res 2000; 6: 249-56.
29. Guerra AN, Fisette PL, Pfeiffer ZA et al. Purinergic receptor regulation of LPS-induced signaling and pathophysiology. J Endotoxin Res 2003; 9: 256-63.
30. Hancock REW, Lehrer R. Cationic peptides: A new source of antibiotics. Trends Biotechnol 1998; 16: 82-8.
31. Ge Y, MacDonald DL, Holroyd KJ et al. In vitro antibacterial properties of pexiganan, an analog of magainin. Antimicrob Agents Chemother 1999; 43: 782-8.
32. Giacometti A, Cirioni O, Del Prete MS et al. Comparative activities of polycationic peptides and clinically used antimicrobial agents against multidrug-resistant nosocomial isolates of Acinetobacter baumannii. J Antimicrob Chemother 2000; 46: 807-10.
33. Braunstein A, Papo N, Shai Y. In vitro activity and potency of an intravenously injected antimicrobial peptide and its DL amino acid analog in mice infected with bacteria. Antimicrob Agents Chemother 2004; 48: 3127-9.
34. Rivas L, Andreu D. Cecropin-melittin hybrid peptides as versatile templates in the development of membrane active antibiotics agents. In: Menestrina G, Dalla Serra M, ads. Pore-Forming Peptides and Protein Toxins. Reading, Berkshire: Harwood Academic Publishers, 2003; 215-59.
35. Vaneschoutte M, Dijkshoom L, Tjernberg I et al. Identification of Acinetobacter genomic species by amplified ribosomal DNA restriction analysis. J Clin Microbiol 1995; 33: 11-5.
36. Boman HC, Boman IA, Andreu D et al. Chemical synthesis and enzymic processing of precursor forms of cecropins A and B. J Biol Chem 1989; 264: 5852-60.
37. Andreu D, Ubach J, Boman A et al. Shortened cecropin A-melittin hybrids. Significant size reduction retains potent antibiotic activity. FEBS Lett 1992; 296: 190-4.
38. Chicharro C, Granata C, Lozano R et al. N-terminal fatty acid substitution increases the leishmanicidal activity of CA(1-7)M(2-9), a cecropin-melittin hybrid peptide. Antimicrob Agents Chemother 2001; 45: 2441-9.
39. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically - Sixth Edition. CLSI, Wayne, PA, 2005.
40. Richardson WP, Sadoff JC. Production of a capsule by Neisseria gonorrhoeae. Infect Immun 1977; 15: 663-4.
41. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Fifteenth International Supplement. CLSI, Wayne, PA, USA, 2005.
42. Anon. Recomendaciones del grupo MENSURA para la selección de antimicrobianos en el estudio de la sensibilidad y criterios para la interpretación del antibiograma. Rev Esp Quimioter 2000; 13: 73-86.
43. Lorian V. Antimicrobial combinations. In: Lorian V, ad. Antibiotics in Laboratory Medicine. MD, USA: Williams and Wilkins, 1996; 339-41.
44. National Committee for Clinical Laboratory Standards. Methods for Determining Bactericidal Activity of Antimicrobial Agents: Approved Standard M26-A. NCCLS, Wayne, PA, USA, 1999.
45. Avrahami D, Shai Y. Bestowing antifungal and antibacterial activities by lipophilic acid conjugation to D,L-amino acid-containing anti-microbial peptides: A plausible mode of action. Biochemistry 2003; 42: 14946-56.
46. Montero A, Ariza J, Corbella X et al. Efficacy of colistin versus β-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii. Antimicrob Agents Chemother 2002; 46: 1946-52.
47. Beringer P. The clinical use of colistin in patients with cystic fibrosis. Curr Opin Pulm Med 2001; 7: 434-40.
48. Musher DM. Streptococcus pneumoniae. In: Mandell D, Bennett JE, Dolin R, ads. Principles and Practice of Infectious Diseases, 6th edn. Philadelphia, USA: Elsevier, 2005; 2392-411.
49. Garcia A, Solar H, Gonzalez C et al. Effect of EDTA on the resistance of clinical isolates of Acinetobacter baumannii to the bactericidal activity of normal human serum. J Med Microbiol 2000; 49: 1047-50.
50. Campos MA, Vargas MA, Regueiro V et al. Capsule polysaccharide mediates bacterial resistance to antimicrobial peptides. Infect Immun 2004; 72: 7107-14.
51. Henry MA, Secombes CJ. The A-layer influences the susceptibility of Aeromonas salmonicida to antibacterial peptides. Fish Shellfish Immunol 2000; 10: 637-42.
52. Scott MG, Yan H, Hancock REW. Biological properties of structurally related α-helical cationic antimicrobial peptides. Infect Immun 1999; 67: 2005-9.
53. Wakabayashi H, Matsumoto H, Hashimoto K et al. N-Acylated and D enantiomer derivatives of a nonamer core peptide of lactoferricin B showing improved antimicrobial activity. Antimicrob Agents Chemother 1999; 43: 1267-9.
54. Boman HG, Wade D, Boman IA et al. Antibacterial and antimalarial properties of peptides that are cecropin-melittin hybrids. FEBS Lett 1989; 259: 103-6.
55. Gough M, Hancock REW, Kelly NM. Antiendotoxin activity of cationic peptide antimicrobial agents. Infect Immun 1996; 64: 4922-7.
56. Friedrich C, Scott MG, Karunaratne N et al. Salt-resistant alpha-helical cationic antimicrobial peptides. Antimicrob Agents Chemother 1999; 43: 1542-8.
57. Nos-Barbara S, Portolés M, Morilla A et al. Effect of hybrid peptides of cecropin A and melittin in an experimental model of bacterial keratitis. Cornea 1997; 16: 101-6.
58. Alberola J, Rodríguez A, Francino O et al. Safety and efficacy of antimicrobial peptides against naturally acquired leishmaniasis. Antimicrob Agents Chemother 2004; 48: 641-3
59. McPhee JB, Lewenza S, Hancock REW. Cationic antimicrobial peptides activate a two-component regulatory system, PmrA-PmrB, that regulates resistance to polymyxin B and cationic antimicrobial peptides in Pseudomonas aeruginosa. Mol Microbiol 2003; 50: 205-17.
60. Devine DA, Hancock REW. Cationic peptides: Distribution and mechanisms of resistance. Curr Pharm Des 2002; 8: 703-14.
61. Hancock RE. Concerns regarding resistance to self-proteins. Microbiology 2003; 49: 3343-5.